Skip to main content

Smith + Nephew Plc Value Stock - Dividend - Research Selection

Smith and nephew

ISIN: GB0009223206 , WKN: 502816

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. It also provides arthroscopic enabling technologies for healthcare providers comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue. In addition, the company offers trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; robotics-assisted surgery, various products, and technologies to assist in surgical treatment of the ear, nose, and throat; knee implant products for specialized knee replacement procedures; and hip implant products for the reconstruction of hip joints. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration; and advanced wound devices, such as traditional and single-use negative pressure wound therapy and hydrosurgery systems. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


How The S.N. Nuclearelectrica (BVB:SNN) Story Is Shifting As Fair Value Stays Put

2026-03-25
The fair value estimate for S.N. Nuclearelectrica sits unchanged at RON 49.00, signalling that the latest review did not prompt a reset of the price target level. This steady figure aligns with how recent Street research on other names has treated valuation updates, where price targets often move in small steps and sometimes remain flat even as analysts weigh execution risks and potential catalysts. As you read on, you will see how this stable RON 49.00 marker fits into the evolving research...

CONMED Taps Andrew Moller As Interim Finance Chief In Demand Slump

2026-03-24
CONMED (NYSE:CNMD) has appointed Andrew Moller as Interim Principal Financial Officer. Moller steps into the role following senior finance positions at Smith & Nephew and Stanley Black & Decker. The appointment comes as the company highlights a challenging demand environment for its business. For investors tracking NYSE:CNMD, the leadership shift in the finance function comes at a time when the stock is trading at $36.63, with a 1 year return of a 39.3% decline and a 3 year return of a...

European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading

2026-03-24
European equities traded in the US as American depositary receipts were lower late Tuesday morning,

How the FTSE grew comfortable with bumper pay for bosses

2026-03-21
British boards are handing chief executives bumper pay awards in a sign that investors are buying the argument that they should approve large...

BlackLine, Smith & Nephew, and More Stocks See Action From Activist Investors

2026-03-20
13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.

[Latest] Global Surgical Stapling Devices Market Size/Share Worth USD 10.14 Billion by 2035 at a 7.2% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

2026-03-18
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Surgical Stapling Devices Market size & share revenue was valued at approximately USD 5.47 Billion in 2025 and is expected to reach USD 5.89 Billion in 2026 and is expected to reach around USD 10.14 Billion by 2035, at a CAGR of 7.2% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Medtronic plc, Ethicon

SNN Launches ALLEVYN COMPLETE CARE Dressing for Wound Management

2026-03-11
Smith + Nephew launches ALLEVYN COMPLETE CARE foam dressing for wound management, expanding its Advanced Wound Management portfolio.

Smith & Nephew plc (SNN) Q4 2025 Earnings Call Transcript

2026-03-02

Smith & Nephew plc 2025 Q4 - Results - Earnings Call Presentation

2026-03-02

Is Smith & Nephew SNATS (SNN) Stock Undervalued Right Now?

2026-02-23
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.